Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H25N7O4 |
| Molecular Weight | 391.4249 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC(N\N=C\C2CCCCC2)=NC3=C1N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O
InChI
InChIKey=XJFMHMFFBSOEPR-DNZQAUTHSA-N
InChI=1S/C17H25N7O4/c18-14-11-15(22-17(21-14)23-20-6-9-4-2-1-3-5-9)24(8-19-11)16-13(27)12(26)10(7-25)28-16/h6,8-10,12-13,16,25-27H,1-5,7H2,(H3,18,21,22,23)/b20-6+/t10-,12-,13-,16-/m1/s1
| Molecular Formula | C17H25N7O4 |
| Molecular Weight | 391.4249 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Binodenoson, a selective adenosine A(2A) receptor agonist, was being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging. Binodenoson for injection under the brand name CorVue was developed for use in patients with or at risk for coronary artery disease (CAD) who are unable to perform a cardiac exercise stress test. CorVue was designed to minimize side effects such as dyspnea, flushing, heart block, and chest pain. Binodenoson did not achieve FDA approval in 2009 due to concerns over equivalence of its efficacy with adenosine.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. | 2005 Mar-Apr |
|
| A new generation of coronary vasodilators in stress perfusion imaging. | 2007 Jun 1 |
|
| Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. | 2009 Nov |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:45:29 GMT 2025
by
admin
on
Wed Apr 02 09:45:29 GMT 2025
|
| Record UNII |
LJA4M1L5LG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C174671
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
m2499
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
144348-08-3
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
DB04853
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
CHEMBL1950554
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
MM-53
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
8174
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
DTXSID60869938
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
9576912
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
LJA4M1L5LG
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY | |||
|
300000034078
Created by
admin on Wed Apr 02 09:45:29 GMT 2025 , Edited by admin on Wed Apr 02 09:45:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
